AI Summary & Key Takeaways
AI InsightFor all patients, median follow-up time was 24 months and median overall survival (OS) was 36 months.
📌 3 Key Takeaways
Abstract
Objectives: The aim of the study was to evaluate demographic characteristics and treatment outcomes of patients with renal cell cancer. Materials and Methods: Data of 100 patients diagnosed with RCC at Atatürk Research and Education Hospital between the years 2005-2014 were analyzed retrospectively. Kaplan-Meier test was performed for survival analysis. Results: Radical nephrectomy was perfomed 64 % of patients, also partial nephrectomy rate was 7%. Histopathologically, clear cell varient's rate was 84%. Most of the patients were stage 4 (55%) and the most common metastatic site was lung (34%). After the development of metastases, first line interferone (IFN) treatment was administered to 62 of patients and 49 of these took tirosine kinase inhibitor after IFN treatment. For all patients, median follow-up time was 24 months and median overall survival (OS) was 36 months. We determined that OS was 30 months and progression free survival (PFS) was 15 months among patients having recieved sunitinib. Fatigue (34.90%) and anemia (27.90%) were the most common grade 3-4 toxicities. In patients who used sunitinib, median PFS in the good, intermediate and poor risk patients according to Memorial Sloan Kettering Cancer Center (MSKCC) criteria respectively were 45.15 and 6 months (p
Özet
Amaç: Çalışmanın amacı, böbrek hücreli karsinomlu (BHK) hastaların demografik özellikleri ve tedavi sonuçlarını değerlendirmektir. Materyal ve Metot: 2005- 2014 yılları arasında Ankara Atatürk Eğitim ve Araştırma Hastanesi'nde BHK tanısı ile takip edilen 100 hastaya ait veriler geriye dönük olarak incelendi. Sağkalım analizi için Kaplan-Meier yöntemi kullanıldı. Bulgular: Hastaların %64'üne radikal nefrektomi, %7'sine parsiyel nefrektomi uygulanmıştı. Histopatolojik olarak berrak hücreli tip %84 oranındaydı. Çoğunluğunu evre IV hastalar oluşturmaktaydı (%55,00) ve en sık metastaz bölgesi akciğerdi (%34). Hastaların 62'sinin metastaz sonrası ilk basamakta interferon (IFN) tedavisi, 49 hastanın ise IFN sonrası tirozin kinaz inhibitörü (TKI) almış olduğu saptandı. Tüm hastaların ortanca takip süresi 24 ay ve ortanca genel sağkalım (GS) 36 ay idi. Sunitinib kullanan hastalarda ise ortanca GS 30 ay ve ortanca progresyonsuz sağkalım (PS) 15 ay bulundu. Grad 3-4 toksisiteler içinde en sık halsizlik (%34,90) ve anemi (%27,90) saptandı. Sunitinib kullanan hastalarda Memorial Sloan Kettering Cancer Center (MSKCC) kriterlerine göre iyi, orta, kötü riskli hastalarda ortanca PS'ler ise sırasıyla 45, 15 ve 6 ay idi (p